InDex to Present Positive Results of Kappaproct for Ulcerative Colitis at Digestive Disease Week Meeting

InDex to Present Positive Results of Kappaproct for Ulcerative Colitis at Digestive Disease Week Meeting
InDex Pharmaceuticals today presents positive results of its lead drug candidate Kappaproct (cobitolimod) to treat moderate to severe active ulcerative colitis (UC) during the Digestive Disease Week congress now underway in Chicago. The Swedish company said in a press release that it is presenting two posters showing that the drug induces remission of UC symptoms. Kappaproct (cobitolimod) binds to the toll-like receptor 9 (TLR9), which enhances its function and leads to production of anti-inflammatory cytokines which help reduce inflammation and heal mucosal wounds. TLR9 is crucial in protection against intestinal damage and for intestinal repair. The first poster, “Binding properties of human TLR-9 receptor to cobitolimod – a candidate for treatment of active Ulcerative Colitis in late stage of clinical development,"  shows the binding affinity of cobitolimod to TLR9. The second, “IL-10 induction properties of the TLR-9 agonist cobitolimod – a candidate for treatment of active Ulcerative Colitis in late stage of clinical development," shows that the drug can induce a dose-dependent release in vitro of the anti-inflammatory cytokine IL-10 from immune cells obtained from both healthy individuals and UC patients. The COLLECT (NCT01493960) trial tested Kappaproct in a placebo-controlled, double-blind, randomized Phase 3 clinical trial that evaluated its effectiveness and safety in 131 chronic active UC patients who had not responded to available therapy. Patients in COLLECT — which took place at 38 sites in seven European countries — received either 30 mg of Kappaproct or a placebo in two separate rectal doses at the study's start and at week four. The resulting study, “Clinical effects of a topically applied Toll-receptor
Subscribe or to access all post and page content.